Study to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis (BIOSEP)

Nantes University Hospital (NUH)

Status: Completed

Conditions: Progressive Multiple Sclerosis

Treatments: Other: Non interventional Study

Study type: Observational

Funder types: Other

Identifiers

NCT03302806

RC16_0232

Details and patient eligibility

About

The purpose of this observational study is to collect efficacy and safety data in real life condition within the first year of treatment in patients with progressive multiple receiving a daily dose of biotine of 300 mg.

Enrollment: 103 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Progressive multiple sclerosis patients with an EDSS score ≤ 7 who have been prescribed high dose of biotin (temporary use administration) at Nantes university hospital (France)

Exclusion criteria

• Patient with remittent recurrent multiple sclerosis
• Pregnant women or women contemplating pregnancy